Taking the "High" Out of High Blood Pressure

SUNNYVALE, CA―(March 28, 2016) ―The medical technology company, PhysioCue, Inc., has released the results of the initial clinical trial of their patented, non-invasive 1.0 Hypertension Reduction Therapy Device that has consistently shown blood pressure reductions of 15 to 25 points (mmHg) in systolic and diastolic readings. Their clinical trial has shown blood pressure levels dropping to “good” and “excellent” levels in 87 percent of the 60 patients who participated in their study.

These results are equivalent to prior clinical studies that measured high blood pressure reduction from prescription drugs, but the PhysioCue therapy is immediate and, unlike drugs, has no negative side effects. PhysioCue has demonstrated that its 1.0 device is the first non-invasive medical therapy to immediately address hypertension. It will also be tested in San Antonio at the Texas Veterans Health Care System and University Hospital under the direction of cardiologist Robert Chilton, M.D.


How PhysioCue’s Hypertension Therapy Device Works

More than 350,000 Americans die every year from hypertension. The American Heart Association (AHA) says that more than 67 million Americans over the age of 20 have hypertension, which is abnormally high blood pressure that can lead to heart disease, heart attacks and strokes.

PhysioCue’s 1.0 Hypertension Reduction Therapy Device uses a patented vascular cooling system that, applied externally for only 5 minutes, targets the carotid artery with a cold-tip therapy that triggers the brain to lower blood pressure naturally, with or without medications. Danen Ventures, TEEC Angels, and Jiuyou Fund are funding the research and development.


About PhysioCue

PhysioCue is a medical technology company that is researching and developing several life science products that are improving patients’ quality of life, extending the life expectancy of consumers. In 2016 and 2017, Physiocue will bring several non-invasive therapy devices to the market that will treat hypertension and migraine/headaches.

PhysioCue will also introduce wearable devices that will help patients better monitor and manage their overall health and vital signs data using a mobile application on their smartphones.

PhysioCue owns the existing and pending patents for the cooling tip technology that is used to treat hypertension, migraines/headaches and other conditions. PhysioCue is headquartered in the heart of Silicon Valley, California.


Contact:          Bruce Burlington, COO



                        440 North Wolfe Road

                        Sunnyvale, CA 94085, U.S.A.